HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].

Abstract
The patient was a 62-year-old man with small-cell lung cancer (limited disease). He was treated with cisplatin (CDDP) plus etoposide(ETP) and concurrent radiotherapy as first-line treatment. Although a complete response was achieved, his pro-GRP elevated 10 months later. He was treated with several anticancer agents including, CDDP plus irinotecan (CPT-11), CPT-11, paclitaxel and amrubicin (AMR). Although, as a monotherapy, the administration of AMR (30 mg/m(2)) for 3 consecutive days (3-day schedule) seemed to be most effective, severe myelosuppression was observed, and this treatment was discontinued. We changed the treatment schedule to biweekly administration of AMR (30 mg/m(2)). The level of pro-GRP decreased, and it was maintained at a similar level for 7 months. No severe toxicity was observed during this period. This case suggests that the bi-weekly administration of AMR may be a useful option for the treatment of small-cell lung cancer when a 3-day AMR schedule is highly myelosuppressive.
AuthorsJun Kurai, Tadashi Igishi, Hisashi Suyama, Masahiro Kodani, Yasushi Fukuoka, Masanori Miyata, Hirokazu Touge, Yasuaki Hasegawa, Kazuto Yasuda, Yutaka Hitsuda, Eiji Shimizu
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 33 Issue 3 Pg. 373-5 (Mar 2006) ISSN: 0385-0684 [Print] Japan
PMID16531722 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anthracyclines
  • Etoposide
  • Irinotecan
  • amrubicin
  • Cisplatin
  • Camptothecin
Topics
  • Anthracyclines (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Marrow (drug effects)
  • Camptothecin (administration & dosage, analogs & derivatives)
  • Carcinoma, Small Cell (drug therapy)
  • Cisplatin (administration & dosage)
  • Drug Administration Schedule
  • Etoposide (administration & dosage)
  • Humans
  • Irinotecan
  • Lung Neoplasms (drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: